Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

79.17 +0.70 (+0.89%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
69 70 Next >
JPMorgan Goes Global With HOLA ETF—Stocks Plus Built‑In Crash Protection
JPMorgan AM launched HOLA, an ETF that aims to generate income from foreign equities while mitigating risk through a laddered options overlay. 
Via Benzinga
Topics ETFs
AstraZeneca's Experimental Therapy Stumbles In Late-Stage Study For Rare Protein Deposit Condition
AstraZeneca's anselamimab missed the main goal in a Phase 3 AL amyloidosis trial but showed promising benefit in a defined patient subgroup. 
Via Benzinga
Trump's Pharma Tariffs Can Hit Novo Nordisk, Says Barclays Expert, But It's 'Difficult' To Predict As Drugmakers Have 'Complex Supply Chains'
Barclays has said that it's hard to predict which firm would be affected the most by pharma tariffs, except for Novo Nordisk. 
Via Benzinga
Topics Government World Trade
GSK Seeks FDA Nod To Broaden RSV Vaccine For Younger At-Risk Adults
FDA accepts GSK's application to expand Arexvy vaccine use to at-risk adults aged 18–49, with a decision expected in the first half of 2026. 
Via Benzinga
AstraZeneca Stock Rises As Experimental Drug Lowers Blood Pressure In Late-Stage Study, Retail’s Yet To React
Via Stocktwits
Price Over Earnings Overview: AstraZeneca
 
Via Benzinga
AstraZeneca's Drug Shows Promise For Resistant Hypertension In Phase 3 Trial
AstraZeneca's Phase 3 trial showed baxdrostat lowered systolic blood pressure in treatment-resistant hypertension with a favorable safety profile. 
Via Benzinga
Baxdrostat met the primary and all secondary endpoints in BaxHTN Phase III trial in patients with uncontrolled or treatment resistant hypertension
From AstraZeneca
Via Business Wire
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
The Benzinga Stock Whisper Index highlights five stocks seeing increased interest from readers during the week and a look at the catalysts that could be driving the attention. 
Via Benzinga
Why Is AbbVie Stock Trading Higher On Thursday?
AbbVie licensed IGI's trispecific myeloma drug ISB 2001 in a deal worth up to $1.925 billion following strong early-phase clinical data. 
Via Benzinga
Merck Strikes $10-Billion Deal For Verona, Secures First-In-Class COPD Drug
Merck is acquiring Verona Pharma for $10 billion, gaining COPD drug Ohtuvayre as part of its strategy to offset Keytruda's looming patent loss. 
Via Benzinga
Topics Intellectual Property
Dow Futures Edge Up As Trump Prepares More Tariff Letters: Freeport, UnitedHealth, Meta, Novo Nordisk, AstraZeneca Among Stocks In Focus
While Dow Jones futures edged up by 0.17% at the time of writing, the S&P 500 futures were up 0.15%. 
Via Stocktwits
Topics ETFs Government Stocks
Artelo Biosciences Analyst See It As An Emerging Biotech
Artelo gets Buy rating from Boral Capital after positive updates on ART27.13, ART26.12, and preclinical success of its candidate for depression. 
Via Benzinga
NIKE, Datadog And Snap Are Among Top 11 Large Cap Gainers Last Week (June 30-July 4): Are The Others In Your Portfolio?
11 best performing large-cap stocks last week, including Symbotic, Nike, First Solar, Datadog, HPE, Summit Therapeutics, Carnival, POSCO, Wynn Resorts, SharkNinja, and Snap 
Via Benzinga
Global Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:MBIO),(NASDAQ:VSTM),(NASDAQ:CRDF),(NASDAQ:AZN) EQNX::TICKER_END 
Via FinancialNewsMedia
Why AstraZeneca Stock Got Thumped on Thursday
Via The Motley Fool
AstraZeneca In $15B Talks For Drug That Could Upend Lung Cancer Treatment
Via Benzinga
Global Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies
From FN Media Group LLC
Via GlobeNewswire
AstraZeneca In Talks To License Summit Therapeutics’ Experimental Lung Cancer Drug: Report
While the terms of the partnership agreement are still being negotiated, it could include an upfront payment worth several billion dollars and milestone payments, Bloomberg reported, while noting that... 
Via Stocktwits
Why AstraZeneca Stock Topped the Market on Tuesday
Via The Motley Fool
Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment?
The company announced a new drug that uses the same mechanism as Eli Lilly's retatrutide. 
Via Investor's Business Daily
3 No-Brainer Stocks to Buy for Under $100 Right Now
Via The Motley Fool
Topics Intellectual Property
Trump Vows To Cut 'The Best Deal' On Drug Prices. What To Expect.
President Donald Trump, ever the negotiator, is angling to lower drug prices through his Most Favored Nation policy. 
Via Investor's Business Daily
Topics Government
DATROWAY® approved in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer
From AstraZeneca
Via Business Wire
FDA Approves AstraZeneca And Daiichi Sankyo's Datroway For EGFR-Mutated Lung Cancer
FDA grants accelerated approval to AstraZeneca's Datroway for EGFR-mutant NSCLC after prior therapies, with a 45% response rate and a $45 million milestone due. 
Via Benzinga
Is the Market Bullish or Bearish on AstraZeneca?
 
Via Benzinga
AstraZeneca Inks Research Pact With China's CSPC Pharmaceuticals Focused On AI-Driven Research, Valued Up To $5.33 Billion
AstraZeneca inks a multibillion-dollar deal with CSPC to co-develop AI-driven therapies for chronic and immune diseases, boosting its presence in China. 
Via Benzinga
AstraZeneca Inks $5.3B Deal With CSPC Pharma For Developing New Oral Drug Candidate, But Retail’s In No Mood To Cheer
CSPC will receive an upfront payment of $110 million as part of the agreement, and is eligible to receive up to $1.62 billion in potential development milestone payments and up to $3.6 billion in sales... 
Via Stocktwits
Topics Artificial Intelligence
Novartis' Fabhalta Delivers Hemoglobin Gains, Reduces Fatigue In Patients With Rare Blood Disorder
Novartis' Fabhalta improved hemoglobin, reduced fatigue and eliminated transfusion need in a Phase 3B PNH study presented at the 2025 EHA Congress. 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
69 70 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.